Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
10 Delectable Specialty Mixed drinks - 2Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- 3What's going on with Katseye? The Manon Bannerman hiatus drama, explained.
- 4Believe Should Unwind? Look at These Scaled down Games
- 5Cyclone Narelle turns Australian skies blood red in ‘apocalyptic’ scenes
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Kids with smartphones by age 12 are at higher risk of health issues, study finds
- A Couple of Reasonable Guitars for 2024
- German official report: Teen social media ban faces legal hurdles
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- Ukraine to get up to 100 French-made Rafale fighter jets
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
